Board, Staff & Committees
CGPA Board of Directors
|Dick Guest, Chair
|Jeff Watson, Vice Chair
|Barry Fishman, Past Chair
|Jim Keon, President
|Jeff Connell, Vice President, Corporate Affairs
|Jessie Pushell, Executive Assistant
|Jody Cox, Director of Federal Government Relations
|Julie Tam, Vice-President Professional & Scientific Affairs
|Paula Rembach, Research Analyst
|Theresa Elmido, Receptionist / Administrator
|Daniel Charron, Director, Quebec
Scientific Affairs Committee
This committee is responsible for liaising with, and providing input to, Health Canada on various scientific issues related to the approval of generic pharmaceuticals at the federal level.
Chair: Dawn Culp, Mylan
Vice-Chair: Gaetano Gallo, Pharmascience
Provincial Regulatory Committee
This committee is responsible for working with provincial health ministries on regulatory issues related to the listing of generic drugs on provincial drug plan formularies.
Chair: Houri Ohan, Teva
Vice-Chair: Sukhvir Hundal, Ranbaxy
Political Action Committee
The committee assists CGPA in its communications with all levels of government.
Chair: Ian Hilley, Mylan
Vice-Chair: Jason Soler, Cobalt
Intellectual Property Committee
This committee provides advice to CGPA on issues related to Canada’s pharmaceutical patent regime.
Chair: Kane Denike, Teva
Vice-Chair: Kent Major, Cobalt
Market Growth Committee
This committee develops strategies to facilitate the increase in generic pharmaceutical sales in Canada and internationally. This group benchmarks international practices and develops options for companies to increase private sector market share.
Chair: Jeff Mehltretter, Mylan
Vice-Chair: Heather J. West, Apotex
Industry Practices Review Board - National
This board is responsible for the education, compliance and enforcement activities required for the implementation of CGPA's code of marketing conduct on a national basis.
Subsequent Entry Biologics Committee
This steering group provides leadership and expert advice on all aspects of biosimilar medicines, which are known as subsequent entry biologics (SEBs) in Canada. This includes liaising with Health Canada as it develops and implements an abbreviated pathway for the timely approval of safe and effective subsequent entry biologics.